about
Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson's disease.Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man.Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury.Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis.Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in MiceRoles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury.Emerging pharmacotherapy for treatment of traumatic brain injury: targeting hypopituitarism and inflammation.The Anti-Inflammatory and Antioxidant Potential of Pistachios (Pistacia vera L.) In Vitro and In Vivo.N-Palmitoylethanolamine-Oxazoline (PEA-OXA) as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury.Fumaric Acid Esters Attenuate Secondary Degeneration after Spinal Cord Injury.The antioxidative property of melatonin against brain ischemia.Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation.Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury.Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats.The Association of Palmitoylethanolamide with Luteolin Decreases Autophagy in Spinal Cord Injury.The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury.Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis.Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice.Adelmidrol, in combination with hyaluronic acid, displays increased anti-inflammatory and analgesic effects against monosodium iodoacetate-induced osteoarthritis in rats.Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia.2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation.Anti-inflammatory and Antioxidant Effects of Flavonoid-Rich Fraction of Bergamot Juice (BJe) in a Mouse Model of Intestinal Ischemia/Reperfusion Injury.A novel protective formulation of Palmitoylethanolamide in experimental model of contrast agent induced nephropathy.Erratum to: Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice.PPAR-α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury.Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease.Potential Eye Drop Based on a Calix[4]arene Nanoassembly for Curcumin Delivery: Enhanced Drug Solubility, Stability, and Anti-Inflammatory Effect.Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of acute and chronic inflammation.2-pentadecyl-2-oxazoline: Identification in coffee, synthesis and activity in a rat model of carrageenan-induced hindpaw inflammation.Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia.Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease.N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice.Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH).2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect.Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis.
P50
Q36332025-2BC88747-B85C-4573-8BB2-F5322C0AE2D0Q36484546-32D49985-FB9C-458A-A367-3CA7310C7FA0Q36663261-AC0D5263-32AC-430B-9968-F7E6EDC4C173Q37098420-ECAAC223-5293-443C-BB31-F0BF2A348E3FQ37334985-87199D98-1478-44A1-9376-C47DB49EEFA8Q38215857-EB1F9BED-235A-4AE1-8E9F-66180C952A0CQ38531165-5352B51A-4A48-410C-8B07-5B4AF8D772E1Q38614387-5BC53A91-B96F-4937-BBE2-DE4B25BB5CE7Q38720918-A6C114A7-4FA4-425C-873E-FC882A63A1B2Q38790365-EA828453-DF83-468C-83F7-E9C193A0617FQ38816026-5D5E4C53-AD7B-4AA7-ADBD-0BFC45F423B9Q38967778-4D7D74D1-DBC2-42D6-9475-B91B871C279CQ38973280-9A8E9F12-E777-468D-9894-D9EF1649CBC4Q39324090-936FBAF8-2C49-4594-810A-8DD5940A7EA1Q40274911-889CCB37-5827-4918-A0BB-363E74331A46Q40768333-CC0BBD64-49AE-41C6-A024-0ECABE65A921Q41467663-5BCF3C44-6702-4BE8-B582-915746A28394Q41585012-298BF000-6457-4778-8813-DB5B8613B498Q41609962-0214081B-0F80-4ECC-B751-B0D3066A8040Q41729974-8438EC3A-3023-4F6D-96AC-973FDF46479CQ41912208-1E77565A-B908-4758-B570-B85CCD9D3077Q42176106-AD185BAA-22D1-4531-B0F3-AD541FECE01BQ42220056-940ACE3F-E1F9-47EE-8D74-9F427776666BQ42239212-A7C57A0B-1B7A-4603-817E-E99FBFD7D853Q42419286-5A07B9F1-39F6-426E-8448-FAFC78660A7DQ42700347-EAF1E67D-F328-46CB-9C77-09E642B45CB8Q42747161-02FCCB37-F786-439E-9527-F359D85E50D2Q46675316-BC6FDE57-93B4-4194-A789-2F8CDBA3E3B8Q48054392-31DEE8AC-4CAC-4BD4-A744-09D467C53AAEQ48238673-82D6483D-80EC-44B3-9326-136C11689938Q48296176-78086E74-FCEB-49D5-B30F-C90649D8E33FQ50040377-91CD3D12-34B8-478A-B6E3-BC00CF32B9FCQ50042498-FA33A010-CBE4-421F-A698-0E60B5F03B4CQ50435071-6138C784-6165-483D-B9BF-E4206ADC49E1Q51510329-1F0F0B7C-5D5D-4E08-B1F1-15EE163C61B0Q51761851-EC0C20BF-F77E-4083-B321-B2E15B992D32Q52573172-088134B5-B5C0-452B-91FE-9F957387EFC4Q52587860-C29963D9-C89C-4C34-B529-5B990C260987Q52608759-6717C69D-4B09-46E3-A3FC-F2EF19C4D518Q53063329-416E110E-531F-4850-A3A7-30D289983B9D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Marika Cordaro
@ast
Marika Cordaro
@en
Marika Cordaro
@es
Marika Cordaro
@nl
type
label
Marika Cordaro
@ast
Marika Cordaro
@en
Marika Cordaro
@es
Marika Cordaro
@nl
prefLabel
Marika Cordaro
@ast
Marika Cordaro
@en
Marika Cordaro
@es
Marika Cordaro
@nl
P106
P1153
56201638100
P2798
P31
P496
0000-0002-3980-0043